Generate Biomedicines, Inc. (GENB) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $128.00K; Additional Paid in Capital, Common StockUSD $1.26B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-129.00K; Retained Earnings (Accumulated Deficit)USD $-804.99M.
- 2026-03-31: Common Stock, Value, IssuedUSD $128.00K; Additional Paid in Capital, Common StockUSD $1.25B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $24.00K; Retained Earnings (Accumulated Deficit)USD $-737.74M.
- 2025-12-31: Common Stock, Value, IssuedUSD $33.00K; Additional Paid in Capital, Common StockUSD $60.19M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $106.00K; Retained Earnings (Accumulated Deficit)USD $-676.29M.
- 2025-06-30: Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD (m).
Generate Biomedicines, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $128.00K | $1.26B | $-129.00K | $-804.99M | $456.05M | 3 month · $8.24M |
| 2026-03-31 | $128.00K | $1.25B | $24.00K | $-737.74M | $514.80M | 3 month · $6.39M |
| 2025-12-31 | $33.00K | $60.19M | $106.00K | $-676.29M | $-615.97M | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | $-517.85M | 3 month · $5.49M |
| 2025-03-31 | (m) | (m) | (m) | (m) | $-471.00M | 3 month · $4.74M |
| 2024-12-31 | (m) | (m) | (m) | (m) | $-434.52M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |